• Lijun Liang, Lei Wang, Panrong Zhu, Youyou Xia, Yun Qiao, Kaiyuan Hui, Chenxi Hu, Yan Ren, and Xiaodong Jiang.
• Department of Radiation Oncology, The Affiliated Lianyungang Hospital of Xuzhou Medical University Tumor Laboratory, The Affiliated Lianyungang Hospital of Xuzhou Medical University, Lianyungang, Jiangsu, People's Republic of China.
• Medicine (Baltimore). 2017 Nov 1; 96 (47): e8725e8725.

RationaleMalignant ascites (MA) is one of the poor prognostic factors for advanced pancreatic cancer and can bring about serious symptoms. The improvement of quality of life for patients is priority. However, there is no standard method for the treatment for pancreatic cancer-mediated MA. Apatinib is a novel and highly selective tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor-2. There are no reports of concurrent apatinib with gemcitabine in patients with pancreatic cancer-mediated MA.Patient ConcernsHerein, we presented a 64-year-old man patient who visited hospital due to abdominal pain for 1 month.DiagnosesHe was initially diagnosed with pancreatic cancer and his first symptom was MA.InterventionsAfter failing in tube drainage and gemcitabine therapy, the patient received gemcitabine combined apatinib orally and after administrated 1 month, the MA was evaluated as nearly clear response according to the RECIST 1.1 standard, and without further need of paracentesis. The CEA and CA199 reached the lowest level after administrating for 2.5 months during the treatment process.Outcomes10.5 months following apatinib administration, the patient achieved a progression-free survival for more than 11 months. Hypertension (grade IV), hand-foot syndrome (grade I) and proteinuria (grade II) were observed.LessonsIt indicated that apatinib concurrent gemcitabine may be a superior choice for pancreatic cancer-mediated MA. Further clinical trials required to confirm its efficacy and safety.Copyright © 2017 The Authors. Published by Wolters Kluwer Health, Inc. All rights reserved.

24 keywords...

hide…